

Study on the effect of metabolites secondary of *Streptomyces* on the bacterium *Pseudomonas aeruginosa* isolated from dog's wound

Estudo do efeito dos metabólitos secundários de Streptomyces na bactéria Pseudomonas aeruginosa isolada em ferida de cão

Sara Abdulkareem Raheem *(ORCID 0000-0003-0241-4226); Dalia Abdulkareem Abdalshheed (ORCID 0000-0003-1369-8826)

Collage of Veterinary Medicine, Baghdad University, Baghdad, Iraq. * corresponding author:
Sarrah.abdulkareem1103a@covm.uobaghdad.edu.iq

Submission: 05/04/2024 | Acceptance: 13/09/2024

ABSTRACT

In Baghdad, Iraq, private veterinary clinics provided one hundred samples between February and December 2022. The study included 72 female and 28 male dogs with wound infections. Thirty isolates of *P. aeruginosa* were identified using biochemical assays and cultural traits. At Tikrit University, ten isolates of *Streptomyces* bacteria were discovered in soil samples collected from various locations in 2022. Biochemical testing and microscopic analysis were used to identify the isolates. *Streptomyces* secondary metabolites were subjected to an antibacterial activity assay at doses of 1024, 512, and 256µg/mL. The results illustrated that raw bacterial extract (*Streptomyces* spp.) exhibited considerable antibacterial activity against all isolates of *P. aeruginosa*. The results demonstrated that a concentration of 1024µg/mL was more efficient than 256µg/mL in combating *P. aeruginosa*. The susceptibility test of all *P. aeruginosa* isolates to 10 antibiotics was carried out by Kirby-Bauer method. The results demonstrated that all isolates were resistant to Ampicillin and Erythromycin (96.66%) followed by Ceftraxone (63.33%), Azithromycin (50%), Levofloxacin (46.66%), Cefotaxime, Ciprofloxacin and Gentamycin (43.33%), Ceftazime (26.66%) and Amikacin (6.66%). The results of the current study indicated that the majority of isolates with high resistance to antibiotics could be affected by *Streptomyces* secondary metabolites to expedite the healing of infected wounds.

KEYWORDS: *Pseudomonas aeruginosa*; *Streptomyces*; secondary metabolites.

RESUMO

Em Bagdá, Iraque, clínicas veterinárias privadas forneceram cem amostras entre fevereiro e dezembro de 2022. Foram incluídos neste estudo 72 cães fêmeas e 28 cães machos com infecções de feridas. Trinta isolados de *P. aeruginosa* foram identificados usando ensaios bioquímicos e características culturais. Na Universidade de Tikrit, dez isolados de bactérias *Streptomyces* foram descobertos em amostras de solo coletadas em várias localidades em 2022. Testes bioquímicos e análise microscópica foram utilizados para identificar os isolados. Metabólitos secundários de *Streptomyces* foram submetidos a um ensaio de atividade antibacteriana nas doses de 1024, 512 e 256µg/ml. Os resultados mostraram que o extrato bacteriano bruto (*Streptomyces* spp.) exibiu considerável atividade antibacteriana contra todos os isolados de *P. aeruginosa*. Os resultados demonstraram que a concentração de 1024µg/mL foi mais eficiente do que 256µg/ml no combate a *P. aeruginosa*. O teste de suscetibilidade de todos os isolados de *P. aeruginosa* a 10 diferentes antibióticos foi realizado pelo método de Kirby-Bauer. Os resultados demonstraram que todos os isolados foram resistentes à Ampicilina e Eritromicina (96,66%), seguidos por Ceftriaxona (63,33%), Azitromicina (50%), Levofloxacina (46,66%), Cefotaxima, Ciprofloxacina e Gentamicina (43,33%), Ceftazidima (26,66%) e Amicacina (6,66%). Os resultados do presente estudo indicaram que a maioria dos isolados com alta resistência a antibióticos poderia ser afetada por metabólitos secundários de *Streptomyces* para acelerar a cicatrização de feridas infectadas.

PALAVRAS-CHAVE: *Pseudomonas aeruginosa*; *Streptomyces*; metabólitos secundários.

INTRODUCTION

Actinomycetes were first observed by Colin in 1875 in the tear glands of the human eye. Currently referred to as *Streptomyces*, they were also isolated from soil, straw, hay, and air by Rossi-Doria in 1891

(OYEDOH et al. 2023). Studies have demonstrated the importance of actinomycetes in the fields of medicine and as a source of soil fertility. Scientific advances in the production of many types of antibiotics, such as antibacterial, antifungal, and antiviral, have played an important role in limiting the growth of some pathological microorganisms (WILLIAM & PAUL 2006). It has been observed that actinomycetes create the majority of antibiotics that are therapeutically effective for treating infections (RAJARAM et al. 2020). It has been suggested that most of the new antibiotics were discovered through soil isolates screening (BANIYA et al. 2018).

Gram-positive filament bacterium Streptomycin is a member of the actinomycetes group, which comprises nearly all soil bacterial species. In addition, the main commercial attraction of these bacteria is the wide variety of antibiotics and anti-cancer compounds they produce (HOPWOOD 2019). Given the current health problems caused by multi-resistant bacteria, finding new antibiotics is a top priority activity. Consequently, bacteria belonging to this genus represent a valuable source for the development of new medicines. To encourage the development of these mysterious routes, various techniques were employed, and some of them had positive results. (AL-AJEELI 2012, BECERRIL et al. 2018, ZHANG et al. 2022).

The Gram-negative bacterium *Pseudomonas aeruginosa* is an opportunistic disease that can infect people and animals (ALHAZMI 2015). In animals, it causes metritis, mastitis, pneumonia, enteritis, and dermatitis (QUINN et al. 1998). *Pseudomonas aeruginosa* cells exhibit significant resistance to widely used antibacterial substances, such as penicillins and tetracyclines (SHAEBTH 2018, VINGOPOULOU et al. 2018). *Pseudomonas aeruginosa* isolates are associated with multidrug resistance (MDR) against more than three distinct classes of antibiotics (HAYATI et al. 2019). Antibiotic-resistant strains of *Pseudomonas aeruginosa*, especially those observed in animals, are becoming increasingly prevalent (WU et al. 2019). The skin acts as a barrier to prevent the entry of bacteria, fungi, and viruses; any breakage of this barrier allows simple microbial infiltration (AL SHAMMAA 2016).

A wound is, by definition, a violation of the integrity of the epithelium of the skin and can affect the architecture, physiology, and functions of the skin. Acute and chronic wounds are two different types of wounds. A common public health problem worldwide is acute or mild wounds. The acute wounds need four to six weeks to heal completely at a physiological level. However, if the healing process continues for more than six weeks without showing any resolution symptoms, the wound may be chronic or more severe wound (CHE SOH et al. 2020). The complicated underlying physiology of each individual makes it difficult to diagnose and treat chronic wounds, which are defined by compromising or interrupting the natural process of wound healing. Thus, the research identified the main causes of infections in canine wounds, and those affected by secondary Streptomyces metabolites. Many virulence factors are present in *Pseudomonas aeruginosa*, including enzymes that break down the effector molecules of the immune system and the components necessary for the cellular and tissue structure of the host. (MATHUR et al. 2006, MARQUES 2015). Nosocomial infections related to *P. aeruginosa* have generated health concerns, mainly due to the high prevalence of antibiotic resistance (ROSENTHAL et al. 2016).

The aim of this study was to: *In vitro*: study of the effects of secondary metabolites of *Streptomyces* spp. *Pseudomonas aeruginosa*

By:

- Isolation and identification of *Pseudomonas aeruginosa* from wound infections in dogs.
- Detecting the virulence factors of *Pseudomonas aeruginosa* using biochemical and molecular methods.
- Determine antibiotic susceptibility and select the most resistant isolate.
- Isolation and identification of filamentous bacteria (*Streptomyces*spp.) from soil samples.
- Extraction of secondary metabolites from filamentous bacteria(*Streptomyces* spp.).

MATERIALS AND METHODS

The project of this study was conducted in Baghdad's province between February and December 2022, with dogs of various ages, genres, and species. The samples were promptly collected and sent to the Faculty of Veterinary Medicine laboratory for molecular analysis and bacterial culture.

Specimens

The specimens were collected with sterile wound coats that had been cleaned with normal saline before collection and then immersed in 5 mL of sterile nutritional broth before being immediately transported to the laboratory.

Isolation of *Pseudomonas aeruginosa* from dog's wound infection

The swabs were incubated for 24 h at 37°C in MacConkey agar, blood agar, and nutrient agar and subcultured in chromogenic *Pseudomonas* agar.

Biochemical tests

All biochemical analyses were performed, including the growth in Nutrient agar at 42 °C, the fermentation of lactose in MacConkey, the oxidase, catalase, and urease tests, and the production of enzyme protease in skimmed milk agar (FORBES et al. 2016).

Antibiotic Susceptibility testing for *Pseudomonas aeruginosa*

Using the agar disc diffusion method, 10 antibiotics were selected according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI 2022) (Table 1) (BAUER et al. 1966) and modified Kirby-Bauer method (OLIVER et al. 2015, SHEHAB & JASSIM 2019, AL ABOOD 2022).

Table 1. The antibiotic disks used in this research.

| No. | Antibiotics discs | Code | Disc potency (µg/disc) | Company | Origin |
|-----|-------------------|------|------------------------|-------------|--------|
| 1 | Levofloxacin | LEV | 5 | Bioanalysis | Turkey |
| 2 | Cefotaxime | TX | 30 | CONDA | Spain |
| 3 | Ceftraxone | CRO | 10 | CONDA | Spain |
| 4 | Azithromycin | AZM | 15 | Bioanalysis | Turkey |
| 5 | Ciprofloxacin | CIP | 30 | Bioanalysis | Turkey |
| 6 | Gentamycin | GN | 10 | Bioanalysis | Turkey |
| 7 | Ampicillin | AM | 25 | Bioanalysis | Turkey |
| 8 | Ceftazime | AZ | 30 | CONDA | Spain |
| 9 | Erythromycin | E | 10 | Bioanalysis | Turkey |
| 10 | Amikacin | AK | 10 | Bioanalysis | Turkey |

Biochemical and molecular techniques for detecting virulence factors in *Pseudomonas aeruginosa*

Capsule detection: This technique uses nanum ink and Triple Sugar Iron to measure motility as described by DAVIS et al. (1990) and QUINN et al. (2004). The production of amilase was determined using a starch medium according to the protocol described by MacFADDIN et al. (2000). Using blood agar, the synthesis of the he

molysin enzyme was measured. Using skim milk agar, enzyme protease synthesis was performed using the procedure described by BENSON (2005). We used nutritional agar, naphthalene, and egg yolk to identify the production of the enzyme phospholipase according to the method described by ATLAS (1995). The production of the enzyme urease was detected using urea medium; the DNA medium was used to monitor DNAase synthesis according to the protocol described by QUINN et al. (2004).

Genome DNA extraction

Pseudomonas aeruginosa was reactivated using genetic techniques by being grown in nutrient agar for 24 h at 37 °C, as well as bacterial DNA isolated using the techniques described by NIKBIN et al. (2012) and WASAN (2021) and using the AccuPower®PCR PreMix, according to the manufacturer's instructions.

Thermocycling programs

Table 2. The thermocycler was adjusted in three stages for the genes (PslA, toxA1, lasA, algD), respectively.

| No. | Steps | Temperature (°C) | Time | Number of cycles |
|-----|----------------------|------------------|---------|------------------|
| 1 | Initial denaturation | 95 | 5 min. | 1 |
| 2 | Denaturation | 95 | 30 sec. | 30 |
| 3 | Annealing | 57.2 | 30 sec. | |
| 4 | Extension | 72 | 1 min. | |
| 5 | Final Extension | 72 | 5 min. | 1 |
| | Store | | 8°C | |

Isolation and identification of *Streptomyces* spp. Sampling of *Streptomyces* spp.

The first step

Ten soil samples were collected from different locations at the College of Veterinary Medicine at the University of Baghdad and the University of Tikrit. As the weight of each sample ranged between (200-250) g of soil, which was extracted from a depth of (10-100) centimeters after removing (2) centimeters of the upper layer, soil samples were placed in sterile containers and completely mixed with CaCO₃ (10% p/p). Ten grams of soil sample were mixed with 100 milliliters of sterilized distilled water (10⁻¹) in a 250 milliliter conical vial and stirred for 10 min. Each vial contained 90 ml of sterile de-ionized water, and each vial contained 10-ml

suspension aliquots. This was done to dilute the sample in series. This final dilution (10^{-5}) used for inoculation (ZHANG et al. 2000). Incubated at 30 °C for a period of 10 days, as mentioned in the development of a formalized method (LEE & HWANG 2002).

The second stage

The soil was treated with a CaCO₃ solution (10% p/v) and incubated at 37 °C for four days before being tested. A ringer solution, which should be sterile, was used to suspend the sample. To separate spores from vegetative cells, test tubes containing (10-2) of the sample dilutions were incubated for 16 h at 45°C. After separating the spores from the vegetative cells, the dilutions were placed in a selective medium (KORN & KUTZNER 1992).

Isolation of *Streptomyces* spp.

Serious dilution crops of soil in agar yeast extract and malt extract incubated at 30°C followed growth for 2 to 7 days and studied the nature of growth in the middle, the odor of the colonies, the color and shape on the surface side and the opposite side of the Petri plate (JOO & RHEE 1997).

Identification of *Streptomyces* spp.

The isolates were identified using biochemical tests, such as catalase, oxidase, urease, DNase, enzyme phospholipase synthesis, and starch hydrolysis.

Antibiotic production by *Streptomyces* spp.

For the production of antibiotics, yeast, malt extract broth, and glucose were distributed in the medium in 500 ml glass vials at a rate of 100 ml per vial, sterilized in an autoclave, left to cool, and then inoculated with 2% of trapped spores, placing the vials in a 120 rpm vibratory incubator at 28 °C for 10 to 14 days (SABARATNAM & TRAQUAIR, 2002).

Antibacterial activity of the secondary metabolites of *Streptomyces* against isolated *P. aeruginosa*

The antibacterial activity of the secondary metabolites of *Streptomyces* against *P. aeruginosa* was determined using the diffusion technique in agar wells at concentrations of 1024, 512 and 256µg/mL (RAHEEM 2014). Table 3 and Fig. 1.

Table 3. Antibacterial activity test of secondary metabolites of *Streptomyces* at concentrations (1024, 512, 256) µg/ml.

| Raw bacterial extract of <i>Streptomyces</i> spp. | | | | | | | | | |
|---|------------|-----------|-----------|---------------|-------------------------------|-----------------|-----------|-----------|---------|
| <i>P. aeruginosa</i> isolated | 1024 µg/ml | 512 µg/ml | 256 µg/ml | Control | <i>P. aeruginosa</i> isolated | 1024 µg/ml | 512 µg/ml | 256 µg/ml | Control |
| P1 | 26 | 20 | 17 | R | P11 | 25 | 21 | 16 | R |
| P2 | 25 | 24 | 20 | R | P12 | 26 | 25 | 20 | R |
| P3 | 26 | 23 | 19 | R | P13 | 26 | 18 | 16 | R |
| P4 | 24 | 20 | 18 | R | P14 | 24 | 22 | 20 | R |
| P5 | 21 | 19 | 16 | R | P15 | 26 | 21 | 20 | R |
| P6 | 25 | 20 | 17 | R | P16 | 25 | 22 | 20 | R |
| P7 | 24 | 20 | 18 | R | P17 | 28 | 26 | 21 | R |
| P8 | 24 | 22 | 20 | R | P18 | 23 | 21 | 20 | R |
| P9 | 28 | 23 | 20 | R | P19 | 25 | 22 | 20 | R |
| P10 | 30 | 22 | 23 | R | P20 | 28 | 24 | 20 | R |
| No. of values | 20 | 20 | 20 | 4 | Multiple comparisons test | Under the Limit | Summary | P-Value | |
| Mean | 25.45 | 21.75 | 19.05 | 0.000 | | | | | |
| Std. Deviation | 2.012 | 2.023 | 1.877 | 0.000 | Control vs. 256 | Yes | ** | <0.0001 | |
| Std. Mean Error | 0.4500 | 0.4523 | 0.4197 | 0.000 | Control vs. 512 | Yes | ** | <0.0001 | |
| | | | | | Control vs. 1,024 | Yes | ** | <0.0001 | |
| ANOVA results | | | <0.0001 | 256 vs. 512 | Yes | ** | 0.0002 | | |
| P-value | | | ** | 256 vs. 1,024 | Yes | ** | <0.0001 | | |
| Significant differences between averages | | | < 0.05 | 512 vs. 1,024 | Yes | ** | <0.0001 | | |




Figure.1. Antibacterial activity of the secondary metabolites of *Streptomyces* against *P. aeruginosa* in (1) 1024 µg/ml, (2) 512 µg/ml, (3) 256 µg/ml and (4) control.

RESULTS AND DISCUSSION

Isolation of *P. aeruginosa* from dog's wound infections

Of the 100 samples (28 males and 72 females) of canine wound infections included in this study, only 30 samples had a positive culture; most samples were identified mainly by morphological characteristics and biochemical tests. Most bacterial isolates developed hemolysis (B) after 24 h of incubation. These huge, flat bacterial colonies with grape smell grew up in the middle of Blood Agar. *P. aeruginosa* was identified as tiny, clear yellow, spherical, and convex colonies in MacConkey agar (non-lactose fermentant). The chromogenic agar Phonomonas was used. The green hue of the colony of *P. aeruginosa* and the change of color from pale or neutral to pale green are the parameters that influence colony color. (ALFRED 2005). The isolates of *P. aeruginosa* were grown on MacConkey agar, chromogenic Pseudomonas agar, and blood agar. You will see red/rosted bastos of *P. aeruginosa*. They fail to preserve their primary color (violet crystal), suggesting that they are Gram-negative bacteria. This result differed from the NOOMI (2018) results for enzyme amylase (3.3%, hemolysin%), enzyme 70%), protease (10%), enzyme phospholipase 83.3%, enzyme urease 100%, enzyme DNAase 80%, pigments 93.3%, and growth in agar nutrient at 42°C.

Genetic techniques for identifying virulence factors

Table 4 shows that, of all *Pseudomonas* isolates, algD and lasA were present in approximately 86.6% of the isolates, toxA1 in 16.6%, and psIA in 96.6%. Figures 2–5 show the results of the PCR experiments. These results differ from those recorded by (ALORNAAOUTI 2015, SCHROEDER et al. 2017, ABEDAL-NABIE 2021).

Table 4. Genes of *Pseudomonas aeruginosa* (virulence factors) identified in infections of canine wounds.

| Dog wound infection samples (100) | | | |
|-------------------------------------|-------------------|-----|------|
| Isolates of <i>Pseudomonas</i> (30) | | | |
| | Virulence factors | No. | % |
| 1 | algD | 26 | 86.6 |
| 2 | lasA | 26 | 86.6 |
| 3 | toxA1 | 5 | 16.6 |
| 4 | psIA | 29 | 96.6 |



Figure 2. PCR product electrophoresis in agarose gel. L: molecular scale of 100 pb, lines (1-30), a positive result for the gene (*algD*) of *P. aeruginosa* at 127 pb.




Figure 3. PCR product electrophoresis in an L agarose gel: a molecular scale of 100 pb, lines 1-30; positive result for the gene of *P. aeruginosa* (*lasA*) at 107 pb.



Figure 4. Electrophoresis of PCR products in agarose gel. L: molecular scale of 100 pb, lines 1-30; positive result for the gene *toxA1* of *P. aeruginosa* at 106 pb.




Figure 5. PCR electrophoresis products in agarose gel. L: molecular scale of 100 pb, lines 1–30; positive result at 178 pb for the gene (*pslA*) of *P. aeruginosa*.

Antibiotic susceptibility of *P. aeruginosa*

According to a recent study, *P. aeruginosa* developed resistance to conventional antibiotics because of drug use. The antibiotic susceptibility test in *P. aeruginosa* showed that 43.33% of the isolates were resistant to cefotaxime (TX), gentamicin (GN), and ciprofloxacin (CIP). Next, 46.66% went to Levofloxacin (LEV), 63.33% to Ceftriaxone (CRO), 50% to Azithromycin (AZM), and 96.66% to Ampicillin (AM) and Erythromycin (E). 26.66% of the isolates were resistant to Ceftazidime (AZ) and 6.66% were resistant to Amikacin (AK), which is consistent with the 2022 ABD (6.67%) (Table 5).

Table 5. Antibiotic susceptibility test results.

| Antibiotics | Antibiotic Disk Test | | | Chi-Square | Sig. | P- Value |
|---------------|----------------------|--------------|-----------|------------|------|----------|
| | Sensitive | Intermediary | Resistant | | | |
| Levofloxacin | 7 | 9 | 14 | 2.600 | NS | 0.2725 |
| Cefotaxime | 8 | 9 | 13 | 1.400 | NS | 0.4966 |
| Ceftriaxone | 5 | 6 | 19 | 12.20 | ** | 0.0022 |
| Azithromycin | 12 | 3 | 15 | 7.800 | * | 0.0202 |
| Ciprofloxacin | 15 | 3 | 12 | 7.800 | * | 0.0202 |
| Gentamycin | 11 | 6 | 13 | 2.600 | NS | 0.2725 |
| Ampicillin | 1 | 0 | 29 | 54.20 | ** | <0.0001 |
| Ceftazidime | 2 | 20 | 8 | 16.8 | ** | 0.0002 |
| Erythromycin | 0 | 1 | 29 | 54.20 | ** | <0.0001 |
| Amikacin | 9 | 19 | 2 | 14.60 | ** | 0.0007 |
| Chi-Square | 32.00 | 57.42 | | 41.71 | | |
| Sig. | ** | ** | | ** | | |
| P-Value | 0.0002 | <0.0001 | | <0.0001 | | |

Strain of *Streptomyces* spp. isolation.

After incubation for 2 to 7 days at a temperature of 30 °C, the results of activation of the isolate in agar yeast extract and malt extract demonstrated the formation of huge colonies up to 10 to 20 mm in diameter, flat, smooth, and cream-colored, and these results agree with (WAKSMAN, 1976). The results showed that the isolation of *Streptomyces* spp. did not produce the enzyme DNase (Table 6). The enzyme DNase analyzes the phosphodiester bond that connects the primary building blocks of DNA, known as nucleotides, to each other, causing the decomposition zones around the colonies that grow in the middle to look purple (NICIEZA et al. 1999, KEMPF et al. 2015, EXNER et al. 2017).

Table 6. Biochemical and enzymatic test results for *Streptomyces* Spp.

| | Tests | Results |
|---|----------------------|---------|
| 1 | Oxidase | + |
| 2 | Catalase | + |
| 3 | Urease | + |
| 4 | DNase | - |
| 5 | phospholipase enzyme | + |
| 6 | Starch hydrolysis | + |

Antibacterial activity of *Streptomyces* secondary metabolites against *P. aeruginosa* in vitro

The secondary metabolites of *Streptomyces* were tested for their antibacterial activity at concentrations of 1024, 512, and 256 g/mL (Figure 6). The results illustrated that in contrast to the control, the raw bacterial extract (*Streptomyces* spp.) significantly inhibited the growth of all *P. aeruginosa* isolates. The results indicate that the concentration of 1024 g/ml was higher than 256 g/ml in terms of the efficacy against *P. aeruginosa*.

It is believed that the raw bacterial extracts of *Streptomyces* species are natural substances with a number of biological functions, such as antioxidants, anticancer agents, and antimicrobials (RIAZ-RAJOKA et al. 2020, MAHDI et al. 2021).




Figure 6. Antibacterial activity of secondary metabolites of *Streptomyces* against *P. aeruginosa* in (1) 1024 µg/mL, (2) 512 µg/mL, (3) 256 µg/mL, and (4) control.

ACKNOWLEDGEMENTS

The author extends his sincere appreciation and gratitude to the respected staff of the Faculty of Veterinary Medicine at the University of Baghdad. Their unwavering support and invaluable assistance throughout this research project was truly praiseworthy.

REFERENCES

- ABD AH. 2022. Antibacterial and antibiofilm activity of purified *Lactobacillus salivarius* exopolysaccharide against *Pseudomonas aeruginosa*. M.Sc. Thesis- in Biology/Microbiology - Mustansiriyah University, Iraq.
- ABEDAL-NABIE WG. 2021. Molecular detection of some virulence genes in *Pseudomonas aeruginosa* Isolation from clinical samples. M.Sc. Thesis- College of Science- Baghdad University, Iraq.
- ALFRED EB. 2005. Microbiological Applications in Laboratory Manuals in General Microbiology. 9.ed. McGraw-Hill Company.
- AL-AJEELI HRAH. 2012. Biological Effectiveness Determination for Antibiotic Extracts from some Local *Streptomyces* Isolates. M.Sc. Thesis -Tikrit University, Iraq.
- ALHAZMI A. 2015. *Pseudomonas aeruginosa*: Pathogenesis and pathogenic mechanisms' International Journal of Biology 7: 44-67.
- ALORNAAOUTI AF. 2015. Study of genotyping and some virulence factors of *Pseudomonas aeruginosa*. Thesis. University of Baghdad- College of Education for Pure Sciences (Ibn-Al-Haitham).
- AL SHAMMAA NF. 2016. Virulence genes profile of *Pseudomonas aeruginosa* local isolates from burns and wounds. Thesis. University of Baghdad- College of Science.
- AL ABOOD MAJ. 2022. Investigation of Some Immunological and Molecular Factors Related to *Pseudomonas Aeruginosa* Caused Burns and Wounds Infection. M.Sc. Thesis- in Genetic Engineering and Biotechnology- Baghdad University, Iraq.
- ATLAS RM. 1995. Principles of Microbiology. Mosloy Year Book, Inc. p: 65-69.
- Bauer, A.W. and Kirby, W.A.W.(1966). Antibiotic susceptibility testing by standardized single disc method. Am.J. Clin. Pathol., 45:493-496.
- BANIYA A et al. 2018. Isolation and screening of antibiotics producing *Streptomyces* spp. from the soil collected around the root of *Alnus nepalensis* from Godawari. Nep. J. Biotech. 6: 46–56.
- BECERRIL A et al. 2018. Uncovering production of specialized metabolites by *Streptomyces argillaceus*: Activation of cryptic biosynthesis gene clusters using nutritional and genetic approaches. PLoS ONE 13: e0198145.
- BENSON SAEB. 2005. Microbiology Applications. 9.ed. New York: Laboratory Manual in general.
- CHE SOH NA et al. 2020. Acute Wound Healing Potential of Marine Worm, *Diopatra claparedii* Grube, 1878 Aqueous Extract on Sprague Dawley Rats. Evidence-Based Complementary and Alternative Medicine.
- CLSI. 2022. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; M10032h Edition PA: CLSI.
- DAVIS BD et al. 1990. Microbiology. 4.Ed. New York: Harper and Row Publishers.
- EXNER M et al. 2017. Antibiotic resistance: what is so special about multidrug-resistant gram-negative bacteria? GMS

- Hyg Infect Control 12: 5.
- FORBES BA et al. 2016. Study Guide for Bailey and Scott's Diagnostic Microbiology-E-Book. Elsevier Health Sciences.
- HAYATI M et al. 2019. Molecular detection of extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* isolates of chicken origin from East Java, Indonesia. *Vet World* 12: 578
- HOPWOOD DA. 2019. Highlights of *Streptomyces* genetics. *Heredity* 123: 23–32.
- JOO GJ & RHEE IK. 1997. Production of glucose isomerase from xylb mutant *Streptomyces chibensis* J- 59. *Kor. J. Appl. Microbiol. Biotechnol.* 25: 75-81.
- KEMPF I et al. 2015. Impact of antibiotic use in the swine industry by Mary D. Barton. *Curr Opin Microbiol* 19: 137-138.
- KORN WF & KUTZNER H. 1992. Family of *Streptomycetaceae* Prokaryotes. New York: Springer-Verlag. p.921-955.
- LEE Y & HWANG K. 2002. Skin thickness of Korean adults. *Surgical and radiologic anatomy* 24: 183.
- MacFADDIN JF. 2000. Biochemical testes for identification of medical bacteria. 3.ed. Pennsylvania: Lippincott Williams and Wilkins.
- MAHDI LH et al. 2021. Establishing novel roles of bifidocin LHA, antibacterial, antibiofilm and immunomodulator against *Pseudomonas aeruginosa* corneal infection model. *International Journal of Biological Macromolecules* 186: 433-444.
- MARQUES DRA. 2015. Prevalência e Susceptibilidade de Isolados Clínicos de *Pseudomonas aeruginosa* numa unidade hospitalar de Portugal. Ph.D. Thesis. Braga: University of Minho.
- MATHUR T et al. 2006. Detection of biofilm formation among the clinical isolates of staphylococci: an evaluation of three different screening methods. *Indian Journal of Medical Microbiology* 24: 25–29.
- NICIEZA RG et al. 1999. Purification characterization and role of nucleases and serine protease in *Streptomyces* differentiation. *Journal of Biology and Chemistry* 23: 20366-20375.
- NIKBIN VS et al. 2012. Molecular identification and detection of virulence genes among *Pseudomonas aeruginosa* isolated from different infectious origins. *Iranian J Microbiol.* 4: 118.
- NOOMI BS. 2018. Detection of virulence factors of *Pseudomonas aeruginosa* in different animals by using bacteriological and molecular methods. *Iraqi Journal of veterinary sciences* 32: 205-210.
- OLIVER A et al. 2015. The increasing threat of *Pseudomonas aeruginosa* high-risk clones. *Drug Resist. Update* 2:41–59.
- OYEDOH OP et al. 2023. Rare rhizo-Actinomycetes: A new source of agroactive metabolites. *Biotechnology Advances*: 108205.
- QUINN PJ et al. 1998. *Clinical Vet Microbiol.* Mosby Pub Co.: 237-242.
- QUINN PJ et al. 2004. *Clinical Veterinary Microbiology.* 6.Ed. London: Mosbyimp. Wolf. p. 434-438.
- RAHEEM SAK. 2014. Study the effect of bacterial extracts of filamentous bacteria (*Streptomyces chromofucus* NS-38) on the bacterium *Staphylococcus aureus* isolated from cases of mastitis in cows. M.Sc. Thesis- College of Veterinary Medicine- Baghdad University, Iraq.
- RAJARAM SK et al. 2020. Extraction and purification of an antimicrobial bioactive element from lichen associated *Streptomyces olivaceus* LEP7 against wound inhabiting microbial pathogens. *JKSUS* 32: 2009–2015.
- RIAZ-RAJOKA MS et al. 2020. *Lactobacillus* exopolysaccharides: new perspectives on engineering strategies, physiochemical functions, and immunomodulatory effects on host health. *Trends Food Sci. Technol.* 103: 36–48.
- ROSENTHAL VD et al. 2016. International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015. Device-associated module. *American journal of infection control* 44: 1495–1504.
- SABARATNAM S & TRAQUAIR JA. 2002. Formulation of a *Streptomyces* biocontrol agent for the suppression of Rhizoctonia damping-off in tomato transplants. *Biological Control* 23: 245–253.
- SCHROEDER M et al. 2017. The Complex Relationship between Virulence and Antibiotic Resistance. *Genes* 8: 39.
- SHAEBTH LJ. 2018. Molecular identification and sequencing of *Pseudomonas aeruginosa* virulence genes among different isolates in Al-Diwaneyah hospital. *Iraqi Journal of Veterinary Sciences* 32: 183-188.
- SHEHAB SK. & JASSIM EH. 2019. Impact of Mint oil and Colistin antibiotic on pilB gene of clinical *Pseudomonas aeruginosa* Isolates from Baghdad, Iraq. *Iraqi journal of biotechnology* 18: 43-54.
- VINGOPOULOU EI et al. 2018. Prevalence and mechanisms of resistance to fluoroquinolones in *Pseudomonas aeruginosa* 213: 102-107.
- WAKSMAN SA. 1976. The Actinomycetes: a summary of current knowledge. New York: The Roland press Co. p.320-325.
- WASAN AD. 2021. Wei-ji: Every crisis is an opportunity. *Pain Medicine* 22: 774-775.
- WILLIAM F & PAUL RJ. 2006. Developing a new resource for drug discovery: Marine actinomycetes bacteria. *Nat. Chem. Biol.* 2: 666-673.
- WU F et al. 2019. Molecular characterization of a multidrug-resistant *Klebsiella pneumoniae* strain R46 isolated from a rabbit. *Intl J Genom* 2019: 5459190.
- ZHANG M et al. 2000. A functional NSP4 enterotoxin peptide secreted from rotavirus-infected cells *J. Virol.* 74: 11663-11670.
- ZHANG H et al. 2022. Positive regulation of the MarR-type regulator slnO and improvement of salinomycin production by *Streptomyces albus* by multiple transcriptional regulation. *Can.J. Microbiol.* 68: 157–163.